Nestlé India Shares Fall Nearly 3% as FSSAI Acts on Infant Nutrition Products
Nestlé India shares fell nearly 3% during intraday trading on Friday after reports that the Food Safety and Standards Authority of India (FSSAI) had initiated legal action concerning its infant nutrition products. The development brought regulatory compliance at the food and beverage company into focus for investors.
According to Reuters, a sample of a Nestlé follow-up formula milk product was classified as substandard after testing identified insufficient biotin. The regulator initiated legal action over the finding. Reuters reported that the company’s shares declined by as much as 2.8%, giving a more precise measure of the nearly 3% intraday fall.
The scrutiny also involves promotional claims associated with NAN Excella Pro Stage 1 and Lactogen Pro 1. FSSAI has raised allegations of misleading claims and regulatory non-compliance involving the infant nutrition products, according to reporting by The Times of India.
The reported issues concern both product composition and the information presented to consumers. These are distinct compliance questions: whether a tested sample meets the required nutritional standards, and whether promotional statements comply with applicable rules.
Nestlé had not commented at the time of the Reuters report. The reported proceedings should be understood as regulatory action and allegations, rather than a final court determination.
The share-price movement reflects an intraday decline, rather than a confirmed closing loss. Further company disclosures and details of the proceedings will be needed to assess the eventual business impact.
